Physician profile
Jacinta Topps
NPI 1609852052
$677.71
in general payments reported to CMS, 2019-2025
15 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $31.62 · 2021: $32.04 · 2022: $53.22 · 2023: $123 · 2024: $122 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $108.90 | 2022-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $102.58 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $94.57 | 2025 | Jornay Pm |
| Corium, LLC | $83.22 | 2023-2024 | Azstarys, Azstarys |
| Cranial Technologies, INC | $50.17 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $48.43 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.70 | 2019 | |
| Tris Pharma INC | $26.99 | 2022-2024 | Dyanavel Xr |
| Alk-Abello, INC | $26.01 | 2025 | Neffy, Odactra, Grastek |
| Sobi, INC | $23.78 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $23.70 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $17.50 | 2022 | |
| Merck Sharp & Dohme LLC | $16.82 | 2024 | M-M-R II, Rotateq, Vaxneuvance |
| Glaxosmithkline, LLC. | $13.75 | 2019 | |
| Pfizer INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinta Topps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.